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Abstract
Background: Limited experience is available on the feasibility and efficacy
of autologous stem-cell transplantation (ASCT) in patients with mantle cell
lymphoma (MCL) beyond 65 years. Design and methods: We analysed 712
patients with MCL treated with ASCT from 2000 to 2007 and reported to the
European Group for Blood and Marrow Transplantation registry. Patients >65
years were compared with patients &lt;65 years for the end points non-relapse
mortality (NRM), relapse incidence, progression-free survival (PFS), and overall
survival (OS). Results: Seventy-nine patients were ≥65 years old. Median time
from diagnosis to ASCT was longer in the elderly patients (11 versus 9 months, P
= 0.005); they had more commonly received at least two treatment lines (62.0%
versus 47.9%, P = 0.02) and were less commonly in first complete remission at
ASCT (35.4% versus 51.2%, P = 0.002). Median follow-up after ASCT was 19
and 25 months, respectively. NRM was comparable at 3 months (3.8% versus
2.5%) a...
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Background: Limited experience is available on the feasibility and efficacy of autologous stem-cell transplantation
(ASCT) in patients with mantle cell lymphoma (MCL) beyond 65 years.
Design and methods: We analysed 712 patients with MCL treated with ASCT from 2000 to 2007 and reported to
the European Group for Blood and Marrow Transplantation registry. Patients >65 years were compared with patients
<65 years for the end points non-relapse mortality (NRM), relapse incidence, progression-free survival (PFS), and
overall survival (OS).
Results: Seventy-nine patients were ‡65 years old. Median time from diagnosis to ASCT was longer in the elderly
patients (11 versus 9 months, P = 0.005); they had more commonly received at least two treatment lines (62.0%
versus 47.9%, P = 0.02) and were less commonly in first complete remission at ASCT (35.4% versus 51.2%,
P = 0.002). Median follow-up after ASCT was 19 and 25 months, respectively. NRM was comparable at 3 months
(3.8% versus 2.5%) and at 5 years (5.6% versus 5.0%). There were no differences in relapse rate (66% versus 55% at
5 years), PFS (29% versus 40%) and OS (61% versus 67%) between both populations of patients.
Conclusion: ASCT beyond 65 years of age is feasible in selected patients with MCL and results in similar disease
control and survival as in younger patients.
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introduction
Mantle cell lymphoma (MCL) is a specific entity of non-Hodgkin
lymphoma (NHL) accounting for 3%–10% of all cases [1, 2].
The disease is biologically characterised by overexpression of
cyclin D1 and the frequently observed t(11;14)(q13;q32), with
important pathophysiological implications [3]. MCL is
characterised by a clear male preponderance with the median age
at diagnosis of 60–65 years. The disease is usually widespread at
diagnosis and carries poorer prognosis than any other type of B-
cell lymphomas with a median survival of only 3–4 years. There
are, however, some indications that prognosis of MCL patients
has improved recently [4].
Age >60 years is a prognostic factor in MCL patients in the
recently published prognostic classification (Mantle Cell
Lymphoma International Prognostic Index) [5]. There are
indications that addition of rituximab to chemotherapy
regimens may improve progression-free survival (PFS) but
without significant improvement in overall survival (OS) in
MCL [6]. Promising treatment results have been observed in
phase II studies using intensive chemotherapeutic regimens
followed by autologous stem-cell transplantation (ASCT) [7, 8]
or without a transplant [9].
ASCT has been advocated as an efficient consolidation therapy
based on several phase II trials [7, 8, 10–12] or based on a registry
analysis [13]. The only prospective randomised study including
122 patients showed that ASCT is superior in terms of PFS when
compared with maintenance therapy with interferon [14].
Limited data are available on the feasibility and efficacy of
ASCT in elderly patients with MCL. This is due to the fact that
only recently the upper age limit for ASCT has shifted from 60
to 65 years or beyond. Current knowledge on the feasibility of
ASCT in the elderly patients is mainly based on small series
including very few patients with MCL [15–18]. A notable
exception is a prospective phase II trial of the Nordic
Lymphoma Group, which included 41 patients ‡60 years [12].
There are no series specifically reporting outcomes of ASCT in
MCL patients >65 years. Therefore, we carried out
a retrospective analysis based on data reported to the European
Group for Blood and Marrow Transplantation (EBMT)
addressing the feasibility and outcome of ASCT for MCL in
patients beyond 65 years of age.
design and methods
The EBMT is a voluntary organisation comprising 640 transplant centres
mainly from Europe. Member centres are required to submit minimal
essential data (MED-A form) from consecutive patients to a central
lymphoma registry in which patients may be identified by subtype of
lymphoma and type of transplantation. Participating EBMT centres are
subject to on-site audits to assess data accuracy and consecutive reporting.
Informed consent was obtained locally according to regulations applicable
at the time of transplantation. Since 1 January 2003, all transplant centres
have been required to obtain written informed consent before data
registration following the Helsinki Declaration 1975.
The EBMT database was used to identify patients with MCL aged 18–75
years treated with a first ASCT from 2000 to 2007. Only fully documented
transplants with MED-B forms (www.ebmt.org) were included in the
analysis. Outcomes were compared by multivariate analysis between cases
included and cases excluded (report with MED-A data only) to ensure
that the study was not biased. Patients ‡65 years of age at ASCT were
compared with younger patients transplanted during the same time period
for various patient- and transplant-related variables as well as outcome
parameters.
statistical methods
The main aim of this study was to investigate the risk of non-relapse
mortality (NRM) and outcome after ASCT in MCL patients ‡65 years at
transplant in relation to those observed in younger patients, adjusting by
the potential differences existing between the both groups. All the analyses
were carried out in the entire patient cohort considering age at ASCT (<65
versus ‡65 years) as the main study variable.
Patient and transplant characteristics were compared between the age
groups using chi-square test or Fisher’s exact test for categorical variables
and the Student’s t-test or Mann–Whitney U test for continuous variables.
The probabilities of PFS and OS were calculated from the time of
transplantation using the Kaplan–Meier product-limit estimate with the
variance estimated by Greenwood’s formula and compared by log-rank test.
Neutrophil engraftment, NRM and relapse or progression after ASCT were
calculated using cumulative incidences to account for competing risks.
Point-wise P values were investigated for NRM at 3 months, 1 year and 5
years after ASCT. Adjusted probabilities for outcomes after transplantation
were estimated using the Cox proportional hazards method to adjust for
patient-, disease- and transplant-related variables. Some risk factors in the
Cox model contained category for ‘unknown’ to avoid loss of information.
The assumption of proportional hazards for each factor in the Cox model
was tested using time-dependent covariates. All variables were tested for
a significant interaction with the main factor under study. All P values were
two sided.
Cumulative incidences were calculated using the NCSS97 software
(Number Cruncher Statistical System, Kaysville, UT). All other
computations were carried out using the SPSS15.0 statistical package (SPSS
Inc., Chicago, IL).
results
eligible patients
Altogether, 712 patients of 2978 patients registered with ASCT
for MCL fulfilled the inclusion criteria for this retrospective
study. No differences were observed between included patients
and those excluded because of missing MED-B information but
otherwise eligible, indicating that cases in the study were
representative for the whole patient group included in the
EBMT registry.
patient and transplant characteristics
There were 79 patients ‡65 years who were compared with
655 younger patients transplanted during the same time
period. The median age of the elderly patients was 67 years
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(range 65–73). Sixty-eight patients were 65–69 years old and
only 11 patients were ‡70 years at the time of transplant. The
median age of the younger patient group was 56 years (29–
64).
The characteristics of the study population and transplants
are presented in Table 1. The age groups were well balanced in
regard of both disease-related and transplant-related
characteristics except that fewer patients in the elderly group
were in first complete remission (CR1) at the time of
transplant. The median follow-up time was 19 months for
patients aged ‡65 years and 25 months in the younger patients
cohort (P = n.s).
engraftment
No differences were observed in the number of CD34+ cells
infused between the two age groups. Also use of granulocyte
colony-stimulating factor was comparable in these groups
(Table 1). No difference was observed in the cumulative
incidence of neutrophil engraftment (96.2% in the elderly
versus 98.1% in younger patients). The median time to
neutrophils >0.5 · 109/l was also comparable (12 versus 12
days) as well as the time to unsupported platelet count of
>20 · 109/l (13 versus 13 days).
non-relapse mortality
The rate of NRM was comparable between older and younger
patients at 3 months (3.8% versus 2.5%), at 1 year (3.8% versus
3.3%), and at 5 years (5.6% versus 5.0%).
In multivariate analysis, age ‡65 at transplant was not
associated with risk of NRM. The only factor of importance in
this respect was the number of treatment lines (two or more)
before ASCT [relative risk (RR) 2.0, 95% confidence interval
(CI) 0.99–4.2, P = 0.052].
relapse risk
No statistically significant differences were found in terms of
risk of relapse or progression after ASCT in elderly compared
with younger patients, with a cumulative incidence of relapse
of 28.4% versus 24.5% at 2 years and 65.8% versus 55.1%
at 5 years, respectively (Figure 1). In multivariate analyses,
several factors were significant for increased relapse risk
including male sex (P = 0.023), elevated serum lactate
dehydrogenase (LDH) at diagnosis (P = 0.001), sensitive
disease versus CR1 at the time of ASCT (P = 0.004),
refractory disease versus CR1 at the time of transplantation
(P < 0.001), and other high-dose regimens versus melphalan,
total body irradiation and cytarabine (P = 0.004). After
adjusting for all prognostic variables, age ‡65 at ASCT had
no significant impact on risk of relapse (RR 1.17, 95% CI
0.79–1.72, P = 0.435).
survival
As expected, disease status at the time of ASCT was the most
important predictive prognostic factor for the transplantation
Table 1. Patient and transplant characteristics according to age at the
time of autologous stem-cell transplantation
n available
(n = 712)
<65 years
(n = 633), (%)
‡65 years
(n = 79), (%)
P
Age, median (range),
years
712 56 (29–64) 67 (65–73) –
Male sex, n (%) 712 487 (76.9) 64 (81.0) n.s.
Stage III–IV 671 89.8 93.2 n.s.
B-symptoms 471 36.8 32.7 n.s
Elevated LDH 511 25.8 22.4 n.s.
Bulky disease
(>10 cm)
538 16.9 12.7 n.s.
Two or more previous
treatment lines
712 47.9 62.0 0.02
Time from dx to
transplant, median
(range), months
712 9 (3–191) 11 (5–101) 0.005
Disease status at
transplant
712
CR1 51.2 35.4 0.002
PR1 24.2 26.6
Other 24.6 38
Poor performance
statusa
456 1.0 7.1 0.01
BEAM regimen 712 57.3 72.2 0.01
TBI in conditioning 712 31.8 15.2 0.002
Stem-cell source PB 712 97.5 98.7 n.s.
No. of CD34+ cells
infused, median
(range), ·106/kg
564 4.6 (1.2–54.0) 4.6 (2.0–26.5) n.s.
G-CSF after stem-cell
infusion
643 62.9 62.2 n.s.
aKarnofsky < 80.
n.s., not significant; LDH, serum lactate dehydrogenase; CR1, first complete
remission; PR1, first partial remission; BEAM, carmustine–etoposide–
cytarabine–melphalan; TBI, total body irradiation; PB, peripheral blood;
G-CSF, granulocyte colony-stimulating factor; dx, diagnosis.
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Figure 1. Cumulative incidence of relapse or progression after
transplantation according to age at the time of ASCT. Dotted line: patients
‡65 years old; solid line: <65 years old. Univariate P = 0.1; P value from
multivariate Cox model P = 0.4. ASCT, autologous stem-cell
transplantation.
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outcome (49.4%, 24.4% and 26.1%, respectively, for those
patients being autografted in CR1, first partial remission and in
patients in more advanced phases). Nevertheless, there were no
statistically significant differences in PFS between older and
younger patients with a probability of PFS at 5 years of 28.6%
compared with 39.9%, respectively (Figure 2). Several factors
predictive for a poor PFS were identified in multivariate
analyses, including male sex (P = 0.008), elevated LDH
(P < 0.001), two or more treatment lines (P = 0.016), sensitive
disease versus CR1 at transplant (P = 0.001), refractory disease
versus CR1 at transplant (P < 0.001) and other conditioning
than melphalan, total body irradiation and cytarabine
(P = 0.006). After adjusting for all these variables, age ‡65 years
at ASCT had no significant impact on PFS after ASCT (RR 1.18,
95% CI 0.82–1.69, P = 0.383).
The OS was not significantly different between the elderly
and younger patients (Figure 3). OS at 5 years was 60.7% in
patients >65 years at transplant and 67.4% in younger patients
(P = 0.15). Factors identified as adverse prognostic variables for
OS in multivariate analyses were B-symptoms at diagnosis
(P = 0.004), elevated LDH at diagnosis (P = 0.007), time from
diagnosis to ASCT >12 months (P = 0.006) and refractory
disease versus CR1 at transplant (P < 001). After adjusting for
these variables, age ‡65 years at ASCT had no significant
impact on OS after transplant (RR 1.4, 95% CI 0.84–2.25,
P = 0.198).
discussion
This retrospective study is based on data collected within the
EBMT registry from >700 transplanted MCL patients with
MED-B reports available. Interestingly, there were 79 patients
(11%) who were at least 65 years old at the time of ASCT. The
main observations were comparable early NRM also in elderly
patients (median age 67 years) and also comparable risks of
relapse, PFS and OS. These observations are of importance
considering that about half of the patients with MCL are
>60–65 years old at the time of diagnosis and that older age is
considered a poor prognostic factor also in this lymphoma
type. In analogy with the situation with diffuse large B-cell
lymphoma [19], the number of transplants in the very elderly
patients with MCL has increased during the last decade.
In our series of MCL patients >65 years, NRM was acceptable
(3.8% at 1 year). This figure seems to be lower than in an earlier
series including 88 ASCT-treated patients aged ‡60 (27 had
MCL) where early NRM was as high as 10% [15]. In a recent
single-centre series including 95 NHL patients >65 years at
transplant (median 68 years; 15 had MCL), NRM at 100 days
was only 4% [16], suggesting that ASCT could also be afforded
in patients up to 70 years of age if they are otherwise fit. Low
NRM observed in this registry series is most likely due to
careful patient selection by the treating physicians.
Unfortunately, we do not have data considering co-morbid
conditions.
The follow-up of this registry series is relatively short taking
into account current outcome of MCL treated with intensive
therapies. The median follow-up time was, however,
comparable in younger and elderly patients. The baseline
characteristics were comparable between the age cohorts except
that more patients were in CR1 in the younger cohort of
patients. Remission status at transplant is known to be an
important prognostic factor for outcome [20, 21]. Both risk of
relapse as well as PFS were comparable in younger and elderly
patients in our analysis.
No plateau was observed in survival curves either in the
younger patients or in the elderly patients. These observations
are skewed by the fact that about half of the patients had
received at least two treatment lines before ASCT and by the
fact that in long-term studies a ‘plateau’ appeared only after an
observation time of ‡6 years [11, 12]. Although it is at present
unclear whether first-line ASCT following intensive induction
is curative in patients with MCL [22, 23], this approach results
in promising long-term survival [11, 12, 24] with a hope that
a fraction of these patients might be cured. Nevertheless, ASCT
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Figure 2. Probability of progression-free survival after transplantation
according to age at the time of ASCT. Dotted line: patients ‡65 years old;
solid line: <65 years old. Univariate P = 0.1; P value from multivariate Cox
model P = 0.4. ASCT, autologous stem-cell transplantation.
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Figure 3. Probability of overall survival after transplantation according to
age at the time of ASCT. Dotted line: patients ‡65 years old; solid line: <65
years old. Univariate P = 0.15; P value from multivariate Cox model
P = 0.2. ASCT, autologous stem-cell transplantation.
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seems to form an important backbone to the treatment strategy
in an important proportion of patients with MCL and has been
shown to be of benefit over non-transplant first-line treatment
in an exploratory analysis of three prospective randomised
studies involving ASCT for MCL [25].
Due to age-related co-morbidity, toxic effects associated with
high-dose therapy might be more critical in elderly patients and
optimal supportive care during the transplant phase appears to
be important to minimise early toxicity in this patient group.
Moreover, patient selection becomes an even more important
issue in elderly patients. Co-morbidity indexes applied in
allogeneic setting [26, 27] might also be useful in elderly
patients before ASCT and should be evaluated prospectively.
Unfortunately, co-morbidity scores were not covered by the
EBMT MED-B forms during the study period and were thus
not available for analysis.
In summary, NRM and disease control in selected patients
with MCL beyond 65 years of age seem to be acceptable and not
significantly different from that in younger patients. Also the
long-term outcome seems to be comparable. Taking into
account these observations and efficacy of ASCT given after
intensive induction therapy, this strategy is worth considering
in selected patients with MCL up to 70 years age.
Improvements in pre- and post-transplant strategies are,
however, needed irrespective of age in order to improve long-
term outcome.
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